In Brief: Searle
Searle: HIV protease inhibitor patents and compounds being made available for licensing. Searle, which has discontinued research of protease inhibitors, is in discussions with several major pharmaceutical firms regarding patent licensing agreements and co-development of two lead protease inhibitor compounds. Glaxo and Vertex recently paid Searle $25 mil. for non-exclusive license to several patent applications and future royalties on experimental protease inhibitor 141W94 (VX-478) to be able to market the product free from intellectual property claims by Searle...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth